Depressive disorder is one of the most common and serious psychiatric diagnosis in paediatric population, often connected with suicidal risk. In recent years, fluoxetine monotherapy is the gold standard in acute phase of depression treatment in children and adolescents, but is not effective enough after an acute phase of treatment. More helpful researches concerning more effective therapeutic strategies of depression in this age are insufficient. The aim of our study is to evaluate the effectiveness and safety of fluoxetine monotherapy in comparison with combined olanzapine/fluoxetine therapy in acute 6-week treatment of depression in adolescence. We found that combined therapeutic strategy, using olanzapine augmentation is predicted to be more useful in the treatment of adolescent depression.
If the inline PDF is not rendering correctly, you can download the PDF file here.
 American psychiatric association. Diagnostic and statistical manual of mental disorders. DSM-5. 5th ed. Arlington VA: American Psychiatric Association; 2013. ISBN 978-0-89042-554-1.
 Corya SA Williamson D Sanger TM Briggs SD et al. (2006). A randomized double-blind comparison of olanzapine/fluoxetine combination olanzapine fluoxetine and venlafaxine in treatment-resistant depression. Depress Anxiety 23:364–372.
 DeFilippis M Wagner KD. Management of treatment-resistant depression in children and adolescents. Paediatr Drugs. 2014 Oct;16(5):353-61.
 Detke HC Delbello MP Landry J Usher RW. Olanzapine/Fluoxetine combination in children and adolescents with bipolar I depression: a randomized double-blind placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2015;54(3):217–224.
 Emslie GJ Heiligenstein JH Wagner KD et al. Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled randomized clinical trial. J Am Acad Child Adolesc Psychiatry 2002; 41 (10): 1205-1215.
 Emslie GJ Rush AJ Weinberg WA et al. A double-blind randomized placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry 1997; 54 (11): 1031-1037.
 Farsky I Smetanka A Dubinska S. Spiritualita pacientov s vybranymi psychiatrickymi diagnozami. Osetrovatelstvi a porodni asistence. 2012;3(3):433–441.
 Food and drug administration (FDA). Antidepressant Medications: Use in Pediatric Patients. 2015. In https://www.cms.gov/Medicare-Medicaid-Coordination/Fraud-Prevention/Medicaid-Integrity-Education/Pharmacy-Education-Materials/Downloads/ad-pediatric-factsheet11-14.pdf
 Heiligenstein JH Hoog SL Wagner KD Findling RL et al. Fluoxetine 40-60 mg versus fluoxetine 20 mg in the treatment of children and adolescents with a less-than-complete response to nine-week treatment with fluoxetine 10-20 mg: a pilot study. J Child Adolesc Psychopharmacol. 2006 Feb-Apr;16(1-2):207-17.
 Kennard B Silva S Vitiello B Curry J et al. TADS Team. Remission and residual symptoms after short-term treatment in the Treatment of Adolescents with Depression Study (TADS). J Am Acad Child Adolesc Psychiatry. 2006 Dec;45(12):1404-11.
 March J Silva S Petrycki S et al. Fluoxetine cognitive-behavioral therapy and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA 2004; 292 (7): 807-820.
 Mayes TL Tao R Rintelmann JW Carmody T et al. Do children and adolescents have differential response rates in placebo-controlled trials of fluoxetine? CNS Spectr. 2007 Feb;12(2):147-54.
 Ondrejka I. Liečba psychofarmakami vdetskom aadolescentnom veku. In: Psychofarmakológia. Vyd. Wolters Kluwer 2016. S. 467-502. ISBN: 978-80-8168-543-9.